Tukysa

Seagen seeks new approval for Tukysa in HER2+ breast cancer
Clinical Trials Arena
Mon, 12/18/23 - 11:32 am
Seagen
Tukysa
breast cancer
HER2+ breast cancer
Seagen reports positive data on Tukysa from Phase III breast cancer trial
Clinical Trials Arena
Thu, 12/7/23 - 11:02 am
Seagen
Tukysa
clinical trials
HER2-positive breast cancer
Seagen’s breast cancer therapy meets main goal in late-stage study
Medical Marketing and Media
Wed, 08/16/23 - 11:34 pm
Seagen
Tukysa
breast cancer
clinical trials
Seagen secures a speedy FDA review on Tukysa as Merck buyout talks reportedly stall
Endpoints
Mon, 09/19/22 - 10:02 pm
Seagen
Merck
M&A
Tukysa
Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe
Yahoo/Zacks.com
Fri, 08/12/22 - 10:12 am
Seagen
Adcetris
Padcev
Tukysa
Tivdak
Merck
M&A
Seagen reports positive Phase II tucatinib data in colorectal cancer
Clinical Trials Arena
Tue, 07/5/22 - 11:54 am
Seagen
Tukysa
metastatic colorectal cancer
clinical trials
Seagen's potential breast cancer blockbuster Tukysa shows promise in colorectal cancer
Fierce Pharma
Mon, 05/23/22 - 06:46 pm
Seagen
Tukysa
breast cancer
colorectal cancer
clinical trials
Seagen’s breast cancer drug Tukysa turned down by NICE
Pharmaforum
Tue, 10/26/21 - 10:36 am
NICE
Seagen
breast cancer
Tukysa
Why Seattle Genetics Stock Jumped 24% in September
Motley Fool
Wed, 10/7/20 - 10:44 am
Seattle Genetics
Merck
oncology
Tukysa
Merck to acquire $1bn equity stake in Seattle Genetics; announces two oncology collaborations
Biopharma Reporter
Mon, 09/14/20 - 10:58 am
Merck
Seattle Genetics
cancer
oncology
ADCs
Tukysa
ladiratuzumab vedotin
FDA approves first new drug under Project Orbis
RAPS.org
Fri, 04/17/20 - 08:42 pm
FDA
Seattle Genetics
Tukysa
advanced HER2-positive breast cancer
breast cancer
Project Orbis